1. Updates From the 2015 Meetings in Hemophilia

3. Program Goal

4. Prophylaxis: History and Challenges

5. Prophylaxis in Adults: The SPINART Trial

6. Stopping Prophylaxis: What Are the Consequences?a

7. Factor VIII Prophylaxis: Long-term Outcomes

8. Trough Levels and Joint Bleeds

9. Extended Half-life Products: Factor IX (FIX) With Albumin

10. Extended Half-life Products: FIX With Fc (FIX-Fc)

11. HB Treatment Advances: Summary

12. Extended Half-life Products: Factor VIII Replacement

13. Extended Half-life Products: N8-GP

14. Extended Half-life Products: BAX-855

15. New Treatment Approaches in Hemophilia: ACE910

16. New Treatment Approaches in Hemophilia: ALN-AT3

17. New Treatment Approaches in Hemophilia: Concizumab

18. Conclusions

19. Abbreviations

20. References

21. References (cont)

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)